Compare CVS Health Corp (CVS) vs Keysight Technologies Inc (KEYS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CVS Health Corp vs Keysight Technologies Inc — how do they compare? CVS Health Corp trades at $86.85 (market cap $112.49B), while Keysight Technologies Inc trades at $379.78 (market cap $64.93B). The key difference: CVS Health Corp is the larger of the two by market cap, and CVS Health Corp pays a 3.02% dividend while Keysight Technologies Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold CVS Health Corp for 83 Days and Keysight Technologies Inc for 56 Days on average.
| CVS | KEYS | |
|---|---|---|
Market Cap | $112.49B | $64.93B |
Volume | 8,467,392 | 1,037,588 |
Sector | Health | Technology |
52-Week High | $110.60 | $387.90 |
52-Week Low | $70.08 | $159.49 |
Typical Hold Time | 83 Days | 56 Days |
Enterprise Value | $174.83B | $65.08B |
Dividend Yield | 3.02% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $87.80, up 1.59% today, with strong analyst support (85% buy ratings) and a $111.20 consensus price target suggesting 27% upside. Recent quarterly earnings have consistently beaten expectations, with Q2 2026 EPS of $2.58 surpassing the $1.87 estimate. Revenue growth remains solid, reaching $402.07B in 2025, though net margins compressed to 1.18%. The technical picture shows bullish momentum with current price near key support at $87.
CVS presents a compelling value opportunity with attractive valuation multiples (P/E 23.21, P/S 0.27) and dividend stability, but faces margin pressure from healthcare cost trends. The stock's upside depends on maintaining earnings momentum amid reimbursement challenges and regulatory scrutiny highlighted in recent legal investigations.
Keysight Technologies (KEYS) trades at $374.66, down 3.41% on the day but remains in a bullish technical trend with strong analyst support. The company reported three consecutive quarterly earnings beats, with Q2 2026 EPS of $3.07 surpassing the $2.48 estimate. Revenue for 2025 reached $5.38 billion, with a net income margin of 15.81%. Recent news highlights growth in AI infrastructure and 6G testing solutions.
Outlook is positive driven by AI and 6G demand, but high valuation multiples pose a risk. The consensus price target of $416.63 implies 11% upside. Key risks include supply constraints and competitive pressures in the semiconductor testing space. Institutional sentiment remains bullish with 81% of analysts rating the stock a buy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →About Keysight Technologies Inc
Keysight Technologies is a leader in the field of testing and measurement, helping electronics OEMs and suppliers alike bring products to market to fit industry standards and specifications. Keysight specializes in the communications market, but also supplies into the government, automotive, industrial, and semiconductor manufacturing markets. Keysight's solutions include testing tools, analytical software, and services. The firm's stated objective is to reduce time to market and improve efficiency at its more than 30,000 customers.
Read more on KEYS →
